Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt(R) ...

A Rhode Island House committee heard powerful testimony from cancer survivors on a bill that would require insurance ...

New York City Health + Hospitals/South Brooklyn Health unveiled a $2 million expansion of its Oncology and Infusion Center, ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

Aplagon is also planning for 2026 a Phase 2 clinical trial for arteriovenous fistula (AVF) maturation failure in Europe, following the successful completion of its Phase 1 AVF trial. The study ...

A Richmond Hill family is asking for community support to fund a medical treatment at Duke University for their daughter ...

European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Donald Trump appears to be so into his shoes he's forcing his loyal staff to partake in his obsession, RadarOnline. com can ...

The elastomeric infusion pumps market is poised to grow from USD 1.15 billion in 2025 to USD 1.49 billion by 2030, at a CAGR ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...